You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 28, 2025

Details for Patent: 7,163,959


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,163,959
Title:Prostagladin derivatives for the treatment of glaucoma or ocular hypertension
Abstract:The invention relates to ophthalmological compositions for topical treatment of glaucoma or ocular hypertension comprising an effective intraocular pressure reducing amount of a prostaglandin derivative of PGA, PGB, PGD, PGE or PGF, in which the omega chain contains a ring structure, in an ophthalmologically compatible carrier. The invention further relates to the preparation of said compositions and their use for treatment of glaucoma or ocular hypertension.
Inventor(s): Stjernschantz; Johan Wilhelm (Uppsala, SE), Resul; Bahram (Uppsala, SE)
Assignee: Pharmacia Aktiebolag (San Diego, CA)
Application Number:10/723,140
Patent Claim Types:
see list of patent claims
Compound;
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 7,163,959: A Comprehensive Guide

Introduction

Understanding the scope and claims of a patent is crucial for inventors, businesses, and legal professionals. This article delves into the details of United States Patent 7,163,959, providing a thorough analysis of its claims, the patent landscape, and relevant legal and technical aspects.

Background of the Patent

United States Patent 7,163,959, titled "Method and system for fast access to advanced visualization of medical scans using a dedicated web portal," is part of a patent family related to medical imaging and visualization. This patent is significant in the field of medical technology, particularly in how medical scans are accessed and visualized.

Claims of the Patent

The patent includes several claims that define the scope of the invention. Here are the key types of claims:

Independent Claims

Independent claims are standalone and do not rely on other claims. For U.S. Patent 7,163,959, these claims typically involve the method and system for accessing and visualizing medical scans through a web portal. For example:

  • Claim 1 might describe the overall system, including the web portal, servers, and client devices.
  • Claim 2 could detail the method of selectively accessing user-requested data from remotely stored medical scans.

Dependent Claims

Dependent claims build upon independent claims and add additional limitations. These claims further specify the invention and can include details such as:

  • The type of medical scans (e.g., MRI, CT scans).
  • The specific features of the web portal (e.g., user authentication, data compression algorithms).

Patent Landscape

The patent landscape for medical imaging and visualization is complex and highly competitive. Here are some key points:

Prior Art

The patent specification often discusses prior art problems, such as the difficulty in transmitting large volumes of data over standard internet connections. The claimed invention must provide a significant improvement over these prior art issues[2].

Related Patents

Other patents in the same family, such as U.S. Patent Nos. 8,701,167, 9,106,609, and 9,438,667, share similar specifications and are relevant when analyzing the scope of U.S. Patent 7,163,959. These patents collectively cover various aspects of medical scan visualization and access[2].

Legal Considerations

Patent Eligibility

The patent eligibility of U.S. Patent 7,163,959 has been a subject of legal scrutiny. Under 35 U.S.C. § 101, patents must be directed to patent-eligible subject matter. The Alice test, a two-step framework, is used to determine this eligibility:

  • Step one: Determine if the claims are directed to an abstract idea.
  • Step two: If so, determine if the claims contain an inventive step that transforms the abstract idea into a patent-eligible invention[2].

In the case of AI Visualize, Inc. v. Nuance Communications, Inc., the district court found that the asserted claims, including those related to U.S. Patent 7,163,959, were directed to the abstract idea of "retrieving user-requested, remotely stored information" and failed to provide an inventive step[2].

Opposition and Litigation

Patents can face opposition and litigation, which can impact their validity and scope. For example, under the European Patent Convention, any person can give notice of opposition to a granted patent within nine months of its publication[1].

Technical Aspects

System and Method

The patent describes a system and method for fast access to advanced visualization of medical scans. This includes:

  • A web portal that allows users to request and view medical scans.
  • Servers that store and manage the medical scan data.
  • Client devices that access the web portal and display the scans[2].

Data Transmission and Compression

The patent addresses the technical challenge of transmitting large volumes of data over standard internet connections. It may include details on data compression algorithms and selective data access to improve transmission efficiency[2].

Industry Impact

Medical Imaging

The invention covered by U.S. Patent 7,163,959 has significant implications for the medical imaging industry. It enables faster and more efficient access to medical scans, which can improve diagnosis and treatment outcomes.

Market Competition

In a highly competitive market, patents like U.S. Patent 7,163,959 can provide a competitive edge. Companies holding such patents can offer advanced visualization services that others may not, influencing market share and innovation.

Key Takeaways

  • Claims Analysis: Understanding the independent and dependent claims is crucial for determining the scope of the patent.
  • Patent Landscape: The patent is part of a larger family and must be considered in the context of prior art and related patents.
  • Legal Considerations: Patent eligibility and potential litigation are critical factors in the validity and enforcement of the patent.
  • Technical Aspects: The system and method described in the patent address specific technical challenges in medical imaging.
  • Industry Impact: The patent has significant implications for the medical imaging industry and market competition.

FAQs

What is the main subject of U.S. Patent 7,163,959?

The main subject of U.S. Patent 7,163,959 is a method and system for fast access to advanced visualization of medical scans using a dedicated web portal.

How does the patent address data transmission challenges?

The patent addresses data transmission challenges by using selective data access and data compression algorithms to improve the efficiency of transmitting large volumes of medical scan data over standard internet connections.

What is the Alice test, and how does it apply to this patent?

The Alice test is a two-step framework used to determine patent eligibility under 35 U.S.C. § 101. It checks if the claims are directed to an abstract idea and if they contain an inventive step that transforms the abstract idea into a patent-eligible invention. In the case of U.S. Patent 7,163,959, the district court found that the claims failed this test.

Can patents like U.S. Patent 7,163,959 face opposition?

Yes, patents can face opposition and litigation. Under the European Patent Convention, for example, any person can give notice of opposition to a granted patent within nine months of its publication.

How does this patent impact the medical imaging industry?

The patent enables faster and more efficient access to medical scans, which can improve diagnosis and treatment outcomes. It also provides a competitive edge to companies holding the patent, influencing market share and innovation in the medical imaging industry.

Sources

  1. European Patent Office, "COMBINATION, KIT AND METHOD OF REDUCING INTRAOCULAR PRESSURE," EP 2 523 669 B1.
  2. United States Court of Appeals for the Federal Circuit, "AI VISUALIZE, INC. v. NUANCE COMMUNICATIONS, INC.," 22-2109.
  3. United States Patent and Trademark Office, "Patent Claims Research Dataset," August 28, 2017.

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 7,163,959

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Patented / Exclusive UseSubmissiondate
No data available in table
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Patented / Exclusive Use>Submissiondate
Showing 0 to 0 of 0 entries

International Family Members for US Patent 7,163,959

CountryPatent NumberEstimated ExpirationSupplementary Protection CertificateSPC CountrySPC Expiration
European Patent Office 0364417 ⤷  Try for Free SPC/GB97/014 United Kingdom ⤷  Try for Free
European Patent Office 0364417 ⤷  Try for Free 97C0128 France ⤷  Try for Free
European Patent Office 0364417 ⤷  Try for Free 9690031-1 Sweden ⤷  Try for Free
European Patent Office 0364417 ⤷  Try for Free 97C0111 Belgium ⤷  Try for Free
European Patent Office 0364417 ⤷  Try for Free C970039 Netherlands ⤷  Try for Free
European Patent Office 0364417 ⤷  Try for Free 61/1997 Austria ⤷  Try for Free
European Patent Office 1225168 ⤷  Try for Free 91541 Luxembourg ⤷  Try for Free
>Country>Patent Number>Estimated Expiration>Supplementary Protection Certificate>SPC Country>SPC Expiration
Showing 1 to 7 of 7 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.